Exact Sciences (NASDAQ:EXAS) 주식

Exact Sciences

Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.

Cathie Wood-Led Ark Invest Dumps $7M Worth Of Palantir Stock Amid Searing Rally

Equities

News

Markets

ETFs

ACCD

ACHR

ADYEY

ARKG

ARKK

ARKQ

ARKX

EXAS

IRDM

RXRX

TWST

2025년 2월 28일 금요일 캐시 우드의 아크 인베스트가 몇 가지 주목할 만한 거래를 진행했다. 그중 가장 두드러진 것은 아처 에비에이션(NYSE:ACHR), 리커전 파마슈티컬스(NASDAQ:RXRX), 템퍼스AI(NASDAQ:TEM), 그리고 이리디움 커뮤니케이션스(NASDAQ:IRDM)의 주식을 매수한 것이다.

아크 인베스트: 템퍼스AI 및 아처 에비에이션 주식 매수, 트위스트 바이오사이언스는 매각

rivian shutter2

Large Cap

Movers

ARWR

CPRT

ESTC

MRNA

RIVN

RKLB

SNAP

SRPT

ULTA

이들 10개 대형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요? 1. 리비안 오토모티브(NASDAQ:RIVN)의 주식이 22.06% 급등했다. 이는 회사가 66억 달러의 에너지부(DOE)의 대출 약정을 확보한 후 발생한 일이다.

리비안, 로켓랩 및 모더나가 지난주 최고 성과를 보여준 10개 대형주 중 일부 (11월 25일-29일)

xr:d:DAFqZwXnoXk:2,j:7421204755476627396,t:23080215

Biotech

Earnings

After-Hours Center

이그젝트 사이언스(NASDAQ:EXAS) 주가는 화요일(5일) 장 마감 이후 3분기 실적을 발표한 후 하락하고 있다. 실적 관련해 자세한 내용을 살펴보자. 실적 세부 사항: 이그젝트 사이언스의 분기 기준 GAAP 주당순손실은 21센트로 애널리스트 컨센서스 예상치 주당순손실 20센트를 하회했다. 분기 매출은 7억 900만 달러로 컨센서스 예상치 7억 1,766만 달러에 미치지 못했다. 

이그젝트 사이언스, 부진한 3분기 실적 발표 이후 30% 가까이 급락, 연간 지침 예상치 하회

Exact Sciences Corporation - Common Stock

Exact Sciences Corp

Exasol AG

Health Care

General

Exact Sciences launch of Oncodetect A New Test Designed To Detect Molecular Residual Disease (MRD) Across Multiple Solid Tumors

Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), a leading provider of cancer screening and diagnostic tests, today announced the publication of a comprehensive review in JAMA Oncology that strengthens the evidence supporting the Oncotype DX Breast Recurrence Score test. The peer-reviewed article titled, "Genomic Assays for Breast Cancer in Diverse Populations: Prognostic and Predictive Insights," affirms that the Oncotype DX test provides accurate and reliable information to help guide breast cancer treatment decisions across all racial and ethnic groups.
While breast cancer mortality has declined overall, non-Hispanic Black women continue to face a 40% higher mortality rate compared to non-Hispanic White womenI. The publication acknowledges these disparities and the need to better understand the complex factors behind them. Despite the prognostic differences between racial and ethnic minority groups, the Oncoytpe DX Breast Recurrence Score test accurately predicts chemotherapy benefit regardless of race or ethnicity. While these disparities highlight the need for broader systemic change, advancing precision oncology remains critical and tools like the Oncotype DX Breast Recurrence Score test ensure treatment decisions are guided by reliable data for every patient.
The largest real-world SEER registry analysis to date—spanning more than 171,000 breast cancer patients and presented at ASCO 2024—provides powerful new evidence that the Oncotype DX test accurately predicts chemotherapy benefit across all racial and ethnic groups. In this study, which is not part of the JAMA Oncology review, the Recurrence Score&#xAE; result predicted chemotherapy benefit in Hispanic, non-Hispanic Black and non-Hispanic White patientsII. These findings add to the body of evidence from key clinical trials—including NSABP&#x2A;-B20 and SWOG†-8814—which confirm that Oncotype DX is the only genomic test proven to predict chemotherapy benefit, the utility of which was further confirmed in randomized clinical trials including TAILORx and RxPONDER III,IV. With no racial or ethnic differences shown in its predictive value, the Oncotype DX test remains a trusted tool to help guide breast cancer treatment decisions for all patients.

Exact Sciences' Oncotype DX Test Gets New Backing in JAMA Oncology, Offers Reliable Insights for Diverse Breast Cancer Patients

Guggenheim analyst Subbu Nambi reiterates Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and maintains $60 price target.

Price Target

Reiteration

Analyst Ratings

Guggenheim Reiterates Buy on Exact Sciences, Maintains $60 Price Target

Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $65 to $55.

Barclays Maintains Overweight on Exact Sciences, Lowers Price Target to $55

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) has been analyzed by 8 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $65.0, a high estimate of $73.00, and a low estimate of $52.00. Highlighting a 7.67% decrease, the current average has fallen from the previous average price target of $70.40. 
<img src="https://www.benzinga.com/files/images/story/2025/1744286466_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Exact Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;-----------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Anthony Petrone &#x7C;Mizuho &#x7C;Announces &#x7C;Outperform &#x7C; $60.00&#x7C;- &#x7C; 
&#x7C;Gerard Cassidy &#x7C;RBC Capital &#x7C;Announces &#x7C;Sector Perform &#x7C; $52.00&#x7C;- &#x7C; 
&#x7C;David Westenberg &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Overweight &#x7C; $70.00&#x7C;$75.00 &#x7C; 
&#x7C;Sung Ji Nam &#x7C;Scotiabank &#x7C;Raises &#x7C;Sector Outperform&#x7C; $73.00&#x7C;$70.00 &#x7C; 
&#x7C;Derik De Bruin &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $65.00&#x7C;$72.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $65.00&#x7C;$70.00 &#x7C; 
&#x7C;Luke Sergott &#x7C;Barclays &#x7C;Announces &#x7C;Overweight &#x7C; $70.00&#x7C;- &#x7C; 
&#x7C;Bruce Jackson &#x7C;Benchmark &#x7C;Maintains &#x7C;Buy &#x7C; $65.00&#x7C;$65.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Exact Sciences's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Exact Sciences's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>All You Need to Know About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Understanding the Numbers: Exact Sciences's Finances</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Exact Sciences's remarkable performance in 3M is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 10.29%. This signifies a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Exact Sciences's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -121.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -30.81%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Exact Sciences's debt-to-equity ratio is below the industry average at 1.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Deep Dive Into Exact Sciences Stock: Analyst Perspectives (8 Ratings)

Mizuho analyst Anthony Petrone initiates coverage on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Outperform rating and announces Price Target of $60.

Initiation

Mizuho Initiates Coverage On Exact Sciences with Outperform Rating, Announces Price Target of $60

Exact Sciences Reports Launch Of Cologuard Plus Colorectal Cancer Screening Test

Analysts' ratings for Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) over the last quarter vary from bullish to bearish, as provided by 7 analysts.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $65.71, along with a high estimate of $73.00 and a low estimate of $52.00. A decline of 6.66% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1741870918_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
The standing of Exact Sciences among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gerard Cassidy</td>
<td>RBC Capital</td>
<td>Announces</td>
<td>Sector Perform</td>
<td>$52.00</td>
<td>-</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$70.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$73.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Exact Sciences's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Exact Sciences's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test is a noninvasive stool-based DNA test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Understanding the Numbers: Exact Sciences's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Exact Sciences displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 10.29%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of -121.19%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): Exact Sciences's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -30.81%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Exact Sciences's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -13.64%, the company may face hurdles in achieving optimal financial returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.15.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Outlook: Exact Sciences Through The Eyes Of 7 Analysts

RBC Capital analyst Gerard Cassidy initiates coverage on Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Sector Perform rating and announces Price Target of $52.

RBC Capital Initiates Coverage On Exact Sciences with Sector Perform Rating, Announces Price Target of $52

On Friday, Feb. 28, 2025, Cathie Wood&#8217;s&nbsp;Ark Invest&nbsp;made some notable trades. The most prominent among these were the purchases of&nbsp;Archer Aviation Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>),&nbsp;Recursion Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>),&nbsp;Tempus AI Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), and&nbsp;Iridium Communications Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRDM#NASDAQ">IRDM</a>).
On the other hand, Ark Invest decided to offload shares of&nbsp;Twist Bioscience Corp&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>),&nbsp;Adyen NV&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ADYEY#OTC">ADYEY</a>),&nbsp;Accolade Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACCD#NASDAQ">ACCD</a>), and&nbsp;Exact Sciences Corp&nbsp;(NCM: EXAS).
The ACHR Trade
Ark Invest purchased a significant number of shares in&nbsp;Archer Aviation Inc&nbsp;across three of its ETFs. The ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) bought 360,583 shares, the ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) acquired 54,699 shares, and the ARK Space Exploration &amp; Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKX#BATS">ARKX</a>) added 17,322 shares.
Based on the closing price of $8.88 on Friday, the total value of these trades is approximately $3.8 million.
The RXRX and TEM Trades
Ark Invest also showed a strong interest in&nbsp;Recursion Pharmaceuticals Inc&nbsp;and&nbsp;Tempus AI Inc. Ark Invest <a href="https://www.benzinga.com/markets/equities/25/02/43963343/cathie-woods-buys-the-dip-in-tempus-ai-coinbase-but-sells-arks-bitcoin-etf-shares-amid-crypto-meltdown">previously purchased</a> a substantial number of shares in Tempus AI despite the company&#8217;s stock falling after reporting mixed fourth-quarter results.
Ark Invest&#8217;s ARK Genomic Revolution ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>) bought 268,467 shares of Recursion Pharmaceuticals and 32,467 shares of Tempus AI.
The ARK Innovation ETF acquired 384,956 shares of Recursion Pharmaceuticals and 49,250 shares of Tempus AI.
Given the closing prices of $56.18 for Tempus AI and $7.51 for Recursion Pharmaceuticals, the total value of these trades is $36.7 million and $0.61 million, respectively.
The IRDM, TWST, ADYEY, ACCD, and EXAS Trades
Ark Invest&#8217;s ARK Innovation ETF bought 73,659 shares of&nbsp;Iridium Communications Inc, while selling 65,290 shares of&nbsp;Twist Bioscience Corp.
The ARK Next Generation Internet ETF sold a small number of shares (52) of&nbsp;Adyen NV.
The ARK Genomic Revolution ETF sold 80,270 shares of&nbsp;Exact Sciences Corp&nbsp;and a minor quantity (232) of&nbsp;Accolade Inc&nbsp;shares.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43900360/bill-gates-has-a-warning-for-the-next-generation-says-be-very-afraid-of-these-4-issues" target="_blank" rel="noreferrer noopener">Bill Gates Has A Warning For The Next Generation, Says Be ‘Very Afraid' Of These 4 Issues</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Image via Ark Invest

Cathie Wood's Ark Invest Loads Up On Tempus AI, Archer Aviation, But Sells Twist Bioscience: Here Are Key Ark Trades This Friday

Piper Sandler analyst David Westenberg maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $75 to $70.

Piper Sandler Maintains Overweight on Exact Sciences, Lowers Price Target to $70

Scotiabank analyst Sung Ji Nam maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Sector Outperform and raises the price target from $70 to $73.

Scotiabank Maintains Sector Outperform on Exact Sciences, Raises Price Target to $73

On Thursday, Guardant Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GH#NYSE">GH</a>) reported fourth-quarter adjusted EPS loss of 62 cents, compared to a loss of 64 cents a year ago, beating the <a target="_blank" href="http://during the premarket session on last check Thursday." rel="noreferrer noopener">consensus loss of 74 cents</a>.
The cancer diagnostic company reported sales of $201.8 million, up 30% year over year, beating the consensus of $192.14 million, driven by an increase in the volume of clinical tests and biopharma tests, which grew <a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b43865627/guardant-health-reports-fourth-quarter-and-full-year-2024-financial-results-and-provides-2025-outl" rel="noreferrer noopener">24% and 16%, respectively</a>.
The company reported approximately 57,300 oncology clinical tests (excluding Shield) and 11,050 biopharma tests.
The increase in precision oncology revenue was also attributable to an increase in reimbursement for tests due to an increase in Medicare reimbursement for the Guardant360 LDT test to $5,000 and an increase in both Medicare Advantage and commercial payer reimbursement.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/01/43110223/guardant-health-gains-medicare-coverage-for-colorectal-cancer-monitoring-test" rel="noreferrer noopener">Guardant Health Gains Medicare Coverage For Colorectal Cancer Monitoring Test</a>
Guidance: Guardant Health forecasts fiscal year 2025 revenue of $850 million—$860 million, versus a consensus of $848.9 million.
Analyst Reaction:
<ul>
<li>William Blair has recently become more optimistic about Guardant. The stock's momentum could continue, especially if investors trust the company's strategy.</li>
<li>While some gains might slow ahead of Exact Sciences Corp's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) midyear results for its blood-based colorectal cancer screening test, analyst Andrew F. Brackmann writes strong financial performance and Guardant's own data updates will support the stock. William Blair maintains <a href="https://www.benzinga.com/quote/GH/analyst-ratings" target="_blank" rel="noreferrer noopener">the Outperform rating</a>.</li>
<li>Stifel analyst Daniel Arias maintains Guardant Health with a Buy and raises the price target from $45 to $53.</li>
<li>JP Morgan analyst Rachel Vatnsdal reaffirms Guardant Health's Overweight rating and raises the price target from $50 to $55.</li>
<li>Raymond James analyst Andrew Cooper reiterates Guardant Health with an Outperform and raises the price target from $39 to $59.</li>
<li>Goldman Sachs analyst Matthew Sykes maintains Guardant Health with a Buy and raises the price target from $49 to $56.</li>
</ul>
Price Action: GH stock is down 10.60% at $42.40 at last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43888128/pfizer-discontinues-hemophilia-gene-therapy-beqvez-interest-wanes" target="_blank" rel="noreferrer noopener">Pfizer Discontinues Hemophilia Gene Therapy Beqvez As Interest Wanes</a></li>
</ul>

Analyst Color

Guidance

Trading Ideas

What's Going On With Cancer Diagnostic Firm Guardant Health On Friday?

During the last three months, 7 analysts shared their evaluations of Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>), revealing diverse outlooks from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $71.14, a high estimate of $86.00, and a low estimate of $65.00. This current average represents a 0.5% decrease from the previous average price target of $71.50. 
<img src="https://www.benzinga.com/files/images/story/2025/1740081673_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
The standing of Exact Sciences among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$70.00</td>
<td>-</td>
</tr>
<tr>
<td>Bruce Jackson</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$65.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$72.00</td>
<td>$75.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$82.00</td>
</tr>
<tr>
<td>Mark Massaro</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Exact Sciences. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Exact Sciences compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Exact Sciences's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Exact Sciences's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/EXAS/analyst-ratings?utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Exact Sciences analyst ratings.</a>
<h2>All You Need to Know About Exact Sciences</h2>
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.
<h3>Exact Sciences's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Exact Sciences displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately 12.78%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Exact Sciences's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -5.4%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Exact Sciences's ROE stands out, surpassing industry averages. With an impressive ROE of -1.19%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Exact Sciences's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -0.57%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Exact Sciences's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.86.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Stocks tumbled Thursday, with all major indices in the red, one day after the S&amp;P 500 notched another all-time high in Wednesday&#8217;s trading session. Investors are weighing uncertainty surrounding tariff policies and disappointing guidance from Walmart while digesting new<a href="https://www.benzinga.com/markets/forex/25/02/43843332/global-markets-mixed-dollar-dips-as-traders-react-to-trumps-tariff-plans-global-markets-today-while-us-slept"> initial jobless claims data.</a>
Mega-retailer Walmart, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>)&#8217;s shares dropped after the company issued fiscal 2026 guidance below analyst expectations, despite fourth-quarter results beating expectations.
Retail investor darling Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) added to Wednesday&#8217;s declines <a href="https://www.benzinga.com/25/02/43849289/whats-going-on-with-palantir-stock-thursday">following a report </a>that the Trump administration told the Pentagon to prepare for sweeping budget cuts and CEO Alex Karp filed a new trading plan to sell up to $1.2 billion shares.
Read Next:<a href="https://www.benzinga.com/25/02/43836832/trump-administration-orders-sweeping-pentagon-cuts-defense-sector-stocks-on-watch"> Trump Administration Orders Sweeping Pentagon Cuts: Palantir, Lockheed Martin, General Dynamics Among Stocks On Watch</a>
Initial jobless claims rose by 5,000 to 219,000, above expectations of 215,000, while continuing claims rose to 186,900 in the first week of February.
WTI crude oil futures rose above $72 per barrel on Thursday, extending its streak of gains to four days as supply concerns outweighed a rise in U.S. stockpiles, according to TradingEconomics. 
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.09% to $97,695. The yield on the 10-year US Treasury note pulled back slightly to 4.5%.
<h2 class="wp-block-heading">Thursday's Performance In Major US Indices, ETFs</h2>
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1 day % chg.</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,911.27</td>
<td>-0.72%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>6,101.27 </td>
<td>-0.7%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>44,036.44</td>
<td>-1.32%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,252.49</td>
<td>-1.31%</td>
</tr>
</tbody>
</table>
</figure>
According to Benzinga Pro data:
<ul>
<li>The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.67% to $608.82. </li>
<li>The SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) was down 1.26% at $441.02</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) slipped 0.7% to $535.72. </li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) was down 1.17% to $223.79. </li>
<li>The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) fell 1.39% to $223.10.</li>
<li>The Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>)&nbsp;rose 0.6% to $92.57. </li>
</ul>
<h2 class="wp-block-heading">Thursday's Stock Movers:&nbsp;</h2>
Cruise stocks Royal Caribbean Cruises Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) and Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCHL#NYSE">NCHL</a>) tumbled, leading consumer discretionary stocks lower. The SPDR Select Sector Fund &#8211; Consumer Discretionary (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) fell 1.44%. 
Stocks reacting to company earnings reports included:&nbsp;
<ul>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>)&nbsp;</li>
<li>Vale S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VALE#NYSE">VALE</a>)&nbsp;</li>
<li>B2Gold Corp. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BTG#AMEX">BTG</a>)</li>
<li>Exact Sciences Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>)</li>
<li>Alamos Gold Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGI#NYSE">AGI</a>)</li>
<li>Walmart, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) </li>
<li>Taseko Mines, Ltd. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/TGB#AMEX">TGB</a>)&nbsp;</li>
<li>Shake Shack, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) </li>
<li>Materialise NV (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTLS#NASDAQ">MTLS</a>) </li>
<li>Hasbro, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HAS#NASDAQ">HAS</a>) </li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) </li>
<li>Jumia Technologies AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JMIA#NYSE">JMIA</a>) </li>
<li>Birkenstock Holding Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) </li>
<li>Sabre Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) </li>
<li>Ardelyx, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) </li>
</ul>
Companies reporting after Thursday's closing bell include:&nbsp;
<ul>
<li>Celsius Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELH#NASDAQ">CELH</a>) </li>
<li>Dropbox, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBX#NASDAQ">DBX</a>) </li>
<li>Iamgold Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IAG#NYSE">IAG</a>) </li>
<li>The RealReal, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) </li>
<li>Nu Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NU#NYSE">NU</a>) </li>
<li>Consolidated Edison, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ED#NYSE">ED</a>) </li>
<li>Rivian Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) </li>
<li>Block, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYZ#NYSE">XYZ</a>) </li>
<li>Booking Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>) </li>
<li>MercadoLibre, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MELI#NASDAQ">MELI</a>) </li>
</ul>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43703014/robert-f-kennedy-confirmed-as-trump-secretary-of-health">Robert F. Kennedy, Vaccine Skeptic, Confirmed As Trump&#8217;s Secretary Of Health: Health Care Stocks To Watch</a></li>
</ul>
Image: Shutterstock.

Market Summary

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

$BTC

ARDX

BABA

BIRK

BKNG

CELH

CVNA

SPDR Dow Jones Industrial Average ETF Trust

JMIA

MELI

MTLS

NCHL

NCLH

PLTR

REAL

SABR

SHAK

VALE

Select Sector SPDR-Consumer Discretionary

Palantir Rally Loses Steam, Walmart Outlook Disappoints: What's Driving Markets Thursday?

WIIM

Exact Sciences shares are trading lower after Barclays and B of A Securities cut their respective price targets on the stock.

B of A Securities analyst Derik De Bruin maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Buy and lowers the price target from $72 to $65.

B of A Securities Maintains Buy on Exact Sciences, Lowers Price Target to $65

Barclays analyst Luke Sergott maintains Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) with a Overweight and lowers the price target from $70 to $65.

Barclays Maintains Overweight on Exact Sciences, Lowers Price Target to $65

Exact Sciences Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported fourth-quarter financial results after the market close on Wednesday. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/02/b43829765/exact-sciences-announces-fourth-quarter-2024-results">from the quarter</a>.
Q4 Earnings: Exact Sciences reported fourth-quarter revenue of $713 million, beating analyst estimates of $701.3 million, according to data from <a href="http://pro.benzinga.com">Benzinga Pro</a>. Total revenue was up 10% on a year-over-year basis. 
Screening revenue totaled&nbsp;$553 million in the quarter, up&nbsp;14% year-over-year. Precision Oncology revenue came in at&nbsp;$161 million,&nbsp;up 0.4% year-over-year.
Exact Sciences generated $47 million of operating cash flow and $11 million of free cash flow during the quarter. The company ended the period with $1.04 billion in cash, cash equivalents and marketable securities.
&#8220;The Exact Sciences team is off to a good start in 2025, building on the momentum we created in the&nbsp;fourth quarter,&#8221; said Kevin Conroy, chairman and CEO of Exact Sciences. 
&#8220;This year is on track to be the most productive in company history, with continued execution from our core business and the launch of three innovative cancer tests. This will power years of growth and profitability, deepen our leadership in diagnostics, and help eradicate cancer by preventing it, detecting it earlier, and guiding personalized treatment.&#8221;
Check This Out: <a href="https://www.benzinga.com/news/earnings/25/02/43831159/carvana-stock-hits-the-brakes-following-q4-earnings-revenue-beat-eps-beat-upbeat-guidance-this-is-just-the-beginning">Carvana Stock Hits The Brakes Following Q4 Earnings: Revenue Beat, EPS Beat, Upbeat Guidance — &#8216;This Is Just The Beginning&#8217;</a>
Outlook: Exact Sciences expects full-year 2025 revenue to be in the range of $3.03 billion to $3.09 billion. Full-year Screening revenue is expected to be in the range of $2.35 billion to $2.39 billion, and Precision Oncology revenue is expected to be between $675 million and $695 million. 
The company anticipates full-year adjusted EBITDA of $410 million to $440 million, versus $323 million in 2024. 
Exact Sciences executives will further discuss the company&#8217;s quarterly results on a conference call set for 5 p.m. ET.
EXAS Price Action: <a href="https://www.benzinga.com/quote/EXAS" target="_blank" rel="noreferrer noopener">Exact Sciences shares</a> were down 2.2% after hours, trading at $49.36 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of Exact Sciences.

Exact Sciences Stock Slides On Q4 Earnings: The Details

Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) reported quarterly sales of $713.00 million which beat the analyst consensus estimate of $701.30 million by 1.67 percent. This is a 10.22 percent increase over sales of $646.88 million the same period last year.

Earnings Beats

Exact Sciences Q4 Sales $713.00M Beat $701.30M Estimate

Press Releases

Exact Sciences Schedules Fourth Quarter 2024 Earnings Call

Management

Dentsply Sirona Appoints Michael Barber and Daniel Scavilla as New Board Members

Exact Sciences Announces Fourth Quarter 2024 Results

Exact Sciences to Participate in March Investor Conferences

Exact Sciences Named 2025 Gallup Exceptional Workplace Award Winner

SERA PROGNOSTICS ANNOUNCES APPOINTMENT OF JEFF ELLIOTT TO ITS BOARD; RYAN TRIMBLE AND MARCUS WILSON TO STEP DOWN

Exact Sciences Launches the Cologuard Plus™ Test, Transforming Colorectal Cancer Screening

Exact Sciences Schedules First Quarter 2025 Earnings Call

JAMA Oncology Publication Strengthens Evidence for Oncotype DX® Test Reliability Across Racial and Ethnic Groups

Exact Sciences Launches the Oncodetect™ Molecular Residual Disease Test

GMED

QTRX

SERA

XRAY

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeiGene, Ltd. - American Depositary Shares

BeiGene

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals

Guggenheim

Barclays

Mizuho

RBC Capital

Piper Sandler

Screenshot 2024-08-30 at 6.27.59 PM

MYNZ

Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones

Screenshot 2024-06-20 at 6.58.26 PM

Mainz Biomed&#39;s ColoAlert Potentially Puts It On A Similar Track As Big Name Cancer Screening Stocks

Screenshot 2024-06-04 at 5.31.42 PM

Mainz Biomed (NASDAQ: MYNZ) Announces Positive Topline Results From Cancer Detection Studies, Including 92% Sensitivity Rate

Comments

Exact Sciences

뉴스

파트너 / 기고자

벤징가 글로벌